Почетна › Немалоклетни карцином плућа › Охајо › Columbus
Kliničke studije za Немалоклетни карцином плућа u gradu Columbus, OH
57 studija za Немалоклетни карцином плућа traži učesnike na lokacijama u gradu Columbus i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Тражи се учесникФаза 2/3
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, Columbus
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Тражи се учесникФаза 3
- Ohio State University Comprehensive Cancer Center, Columbus
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Тражи се учесникФаза 3
- Mount Carmel East Hospital, Columbus
- The Mark H Zangmeister Center, Columbus
- Mount Carmel Health Center West, Columbus
- и још 3
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
Тражи се учесникФаза 3
- The James Cancer Hospital and Solove Research Institute, Columbus
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Тражи се учесникФаза 3
- Ohio State University, Columbus
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Тражи се учесникФаза 3
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T, Columbus
- OhioHealth Riverside Methodist Hospital, Columbus
Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial
Тражи се учесникФаза 2
- Ohio State University Comprehensive Cancer Center, Columbus
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Тражи се учесникФаза 1/2
- Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Тражи се учесникОпсервациона студија
- Memorial Hospital, Marysville · 27 ми удаљено
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Тражи се учесникФаза 1
- The Ohio State University (OSU) Wexner Medical Center, Columbus
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Тражи се учесникФаза 3
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T, Columbus
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Тражи се учесникФаза 1/2
- The Jame Outpatient Care West Campus, Columbus
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Тражи се учесникФаза 2
- Ohio State University Comprehensive Cancer Center, Columbus
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Тражи се учесникФаза 1/2
- Ohio State University CRS, Columbus
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Тражи се учесникФаза 2
- Ohio State University Comprehensive Cancer Center, Columbus
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Тражи се учесникФаза 3
- Ohio State University Hospitals, Columbus
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Тражи се учесникФаза 2/3
- Mark H. Zangmeister Cancer Center, Columbus
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Тражи се учесникФаза 1/2
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0015), Columbus
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
Тражи се учесникОпсервациона студија
- Ohio State University Comprehensive Cancer Center ( Site 0015), Columbus
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Тражи се учесникФаза 1/2
- The James Cancer Hospital and Solove Research Institute, Columbus
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Тражи се учесникФаза 1/2
- The Mark H Zangmeister Center /ID# 272502, Columbus
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Тражи се учесникОпсервациона студија
- The Ohio State University Comprehensive Cancer Center, Columbus
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Тражи се учесникФаза 2
- Local Institution - 0176, Columbus
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Тражи се учесникФаза 1/2
- Ohio State University Comprehensive Cancer Center, Columbus
SMP-3124LP in Adults With Advanced Solid Tumors
Тражи се учесникФаза 1/2
- Ohio State University, Columbus
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Тражи се учесникФаза 1
- Ohio State University, Columbus
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Тражи се учесникФаза 2
- Ohio State University Comprehensive Cancer Center, Columbus
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Тражи се учесникФаза 2
- Ohio State University Comprehensive Cancer Center, Columbus
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Тражи се учесникФаза 2/3
- Columbus Oncology and Hematology Associates Inc, Columbus
- Riverside Methodist Hospital, Columbus
- Grant Medical Center, Columbus
- и још 7
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Тражи се учесникФаза 1
- The Ohio State University, Columbus
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Тражи се учесникФаза 1
- ALX Center 10, Columbus
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Тражи се учесникФаза 3
- The Ohio State University, Columbus
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Тражи се учесникФаза 1/2
- Local Institution - 0102, Columbus
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
Тражи се учесникФаза 1
- Ohio State University, Columbus
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Тражи се учесникФаза 3
- Clinical Study Sites, Columbus
- Clinical Study Site, Columbus
Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
Тражи се учесникФаза 1
- Ohio State University Comprehensive Cancer Center, Columbus
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
Тражи се учесникФаза 1/2
- Ohio State University Comprehensive Cancer Center, Columbus
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Тражи се учесникФаза 3
- Ohio State University Comprehensive Cancer Center, Columbus
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Тражи се учесникФаза 1/2
- The Ohio State University, Columbus
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Тражи се учесникФаза 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
Тражи се учесникФаза 1
- Ohio State University, Columbus
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
Тражи се учесникФаза 1
- Local Institution - 0045, Columbus
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Тражи се учесникФаза 3
- Ohio State University Comprehensive Cancer Center, Columbus
Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy
Тражи се учесникЗдраве особе су добродошле
- Ohio State University Comprehensive Cancer Center, Columbus
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Тражи се учесникФаза 2
- Ohio State University Comprehensive Cancer Center, Columbus
Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer
Тражи се учесник
- Ohio State University Comprehensive Cancer Center, Columbus
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Тражи се учесникФаза 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Тражи се учесникФаза 2
- Mount Carmel East Hospital, Columbus
- The Mark H Zangmeister Center, Columbus
- Mount Carmel Grove City Hospital, Grove City · 7 ми удаљено
- и још 2
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Тражи се учесникФаза 1/2
- The Ohio State University Wexner Medical Center, Columbus
Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer
Тражи се учесникФаза 2
- Ohio State University Comprehensive Cancer Center, Columbus
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Тражи се учесникФаза 2
- Ohio State University Comprehensive Cancer Center, Columbus
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
Тражи се учесникФаза 2
- Ohio State University Comprehensive Cancer Center, Columbus
PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Тражи се учесникФаза 1
- Ohio State University Comprehensive Cancer Center, Columbus
GEMINI-NSCLC: NSCLC Biomarker Study
Тражи се учесникОпсервациона студија
- Ohio State University, Columbus
- OhioHealth Reseach Institute, Columbus
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Тражи се учесникФаза 1/2
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Тражи се учесникОпсервациона студија
- Massive Bio SYNERGY-AI site, Columbus
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Тражи се учесникФаза 1/2
- The Ohio State University, Columbus
Studije za Немалоклетни карцином плућа u drugim gradovima
- Houston, TX143 студија
- New York City, NY123 студија
- Arlington, VA111 студија
- Nashville, TN97 студија
- Los Angeles, CA92 студија
- Boston, MA87 студија
- St. Louis, MO68 студија
- Baltimore, MD60 студија
- San Antonio, TX60 студија
- Chicago, IL59 студија
- Seattle, WA55 студија
- Washington, DC55 студија
Ostale studije u gradu Columbus
- Рак (све врсте)40 студија
- Рак дојке39 студија
- Рак јајника39 студија
- Рак плућа36 студија
- Akutna mijeloidna leukemija34 студија
- Hronična limfocitna leukemija29 студија
- Метастатски карцином25 студија
- Многи мијелом25 студија
- Рак простате25 студија
- Карцином ендометријума24 студија
- Колоректални карцином24 студија
- Меланом21 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.